Incyte Corp. (INCY)

64.91
NASDAQ : Health Technology
Prev Close 64.91
Day Low/High 0.00 / 0.00
52 Wk Low/High 60.23 / 117.95
Avg Volume 1.41M
Exchange NASDAQ
Shares Outstanding 212.58M
Market Cap 13.19B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Incyte Announces Data For Pemigatinib, Its Selective FGFR Inhibitor, To Be Featured At The ESMO 2018 Congress

Incyte Announces Data For Pemigatinib, Its Selective FGFR Inhibitor, To Be Featured At The ESMO 2018 Congress

Incyte (Nasdaq:INCY) announces that interim Phase 2 data on its investigational, selective FGFR1/2/3 inhibitor, pemigatinib (INCB54828), will be presented at the upcoming European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich,...

Tesla, Facebook, Amazon and Netflix Lead the Nasdaq's Sharp Decline

Tesla, Facebook, Amazon and Netflix Lead the Nasdaq's Sharp Decline

The Nasdaq is down more than 2% on Thursday as tech shares sink.

Incyte Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Liberty Global

Incyte Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Liberty Global

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Film Showcasing Four Unique MPN Stories.

Film Showcasing Four Unique MPN Stories.

Today on MPN Awareness Day and throughout September, Blood Cancer Awareness Month, Incyte Corporation (Nasdaq:INCY) is shining a light on myeloproliferative neoplasms (MPNs).

Incyte Announces Positive Data From Phase 2b Trial Of Ruxolitinib Cream In Patients With Atopic Dermatitis

Incyte Announces Positive Data From Phase 2b Trial Of Ruxolitinib Cream In Patients With Atopic Dermatitis

Incyte Corporation (Nasdaq:INCY) today announced positive results from its randomized, dose-ranging, vehicle- and active-controlled Phase 2b study evaluating ruxolitinib cream in patients with atopic dermatitis (AD) who are candidates for topical therapy.

Foundation Medicine

Foundation Medicine

Incyte Corporation (NASDAQ:INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx...

Incyte Announces Chief Financial Officer David Gryska To Retire At The End Of 2018

Incyte Announces Chief Financial Officer David Gryska To Retire At The End Of 2018

Incyte Corporation (Nasdaq:INCY) today announced that David Gryska, Executive Vice President and Chief Financial Officer, intends to retire at the end of 2018 and that Incyte has launched a search for his replacement.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the Morgan Stanley 16 th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 10:00 am EDT in New York.

Incyte Moves Up In Analyst Rankings, Passing Total System Services

Incyte Moves Up In Analyst Rankings, Passing Total System Services

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Incyte Corporation has taken over the #197 spot from Total System Services, Inc. , according to ETF Channel.

Incyte Reports 2018 Second Quarter Financial Results And Updates On Key Clinical Programs

Incyte Reports 2018 Second Quarter Financial Results And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2018 second quarter financial results, highlighting strong growth in total product-related revenue and providing a status update on the Company's development portfolio.

Study Published In The Lancet Shows Benefit Of Baricitinib 4 Mg For The Treatment Of Systemic Lupus Erythematosus (SLE)

Study Published In The Lancet Shows Benefit Of Baricitinib 4 Mg For The Treatment Of Systemic Lupus Erythematosus (SLE)

INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet.

Incyte To Report Second Quarter Financial Results

Incyte To Report Second Quarter Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its second quarter 2018 financial results conference call and webcast for 8:00 a.

10 Large-Cap Stocks With At Least 40% Upside Potential

10 Large-Cap Stocks With At Least 40% Upside Potential

On the search for promising stocks, give these 10 names from Goldman Sachs a consideration.

Incyte To Present Diversified Development Portfolio And Opportunities For Accelerated Growth At 2018 Investor And Analyst Event

Incyte To Present Diversified Development Portfolio And Opportunities For Accelerated Growth At 2018 Investor And Analyst Event

Incyte Corporation (Nasdaq:INCY) will host an investor and analyst event in New York City today to provide a comprehensive update on the Company's growth opportunities and late-stage development portfolio.

Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint Of Overall Response Rate For Ruxolitinib (Jakafi®) In Steroid-Refractory Acute Graft-Versus-Host Disease

Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint Of Overall Response Rate For Ruxolitinib (Jakafi®) In Steroid-Refractory Acute Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced positive topline results from its ongoing pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi ®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute...

Incyte Becomes #34 Most Shorted Nasdaq 100 Component, Replacing Illumina

Incyte Becomes #34 Most Shorted Nasdaq 100 Component, Replacing Illumina

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Lilly To Unveil New Data At The Annual European Congress Of Rheumatology, Furthering Commitment To Scientific Discovery In Immunology

Lilly To Unveil New Data At The Annual European Congress Of Rheumatology, Furthering Commitment To Scientific Discovery In Immunology

Highlights include new Phase 2 data for baricitinib in systemic lupus erythematosus

Lifshitz & Miller LLP Announces Investigation Of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc., And Spectrum Brands Holdings, Inc.

Lifshitz & Miller LLP Announces Investigation Of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc., And Spectrum Brands Holdings, Inc.

NEW YORK, June 5, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. (ARMO) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of ARMO to Eli Lilly, whereby shareholders will receive $50.

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets For The Treatment Of Adults With Moderately-to-Severely Active Rheumatoid Arthritis

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets For The Treatment Of Adults With Moderately-to-Severely Active Rheumatoid Arthritis

The approval of OLUMIANT is based on the Phase 3 clinical trial program that demonstrated efficacy for difficult to treat patients1

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 2:40 pm (PDT) / 5:40 pm (EDT) in...

Sirius XM Radio, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Sirius XM Radio, Teva Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer weighs in on Sirius XM Radio, Teva Pharmaceuticals, iQIYI, Blue Apron, Shopify, Incyte, E*Trade Financial and more.

Big Turnaround Stories: Cramer's 'Mad Money' Recap (Wednesday 5/23/18)

Big Turnaround Stories: Cramer's 'Mad Money' Recap (Wednesday 5/23/18)

Jim Cramer tells investors to keep their eyes open for companies making changes -- that's what's being rewarded.

Incyte Reports 2018 First-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Reports 2018 First-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2018 first-quarter financial results, highlighting strong growth in total product-related revenue and providing a status update on the Company's development portfolio.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 8:40 am PDT in Las Vegas.

Incyte Highlights Abstracts Accepted For Presentation At The 2018 ASCO Annual Meeting

Incyte Highlights Abstracts Accepted For Presentation At The 2018 ASCO Annual Meeting

Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts from its research and development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois from June 1-5, 2018.

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Lilly's chairman and CEO David Ricks said in an earnings call that he was confident in the risk-benefit profile for both proposed doses of the new drug.

TheStreet Quant Rating: D+ (Sell)